Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Goldman Sachs

Bausch Health Companies Inc. (BHC) Management Presents at Goldman Sachs Fifth Annual Leveraged Finance Conference (Transcript)

Bausch Health Companies’ stock, formerly called Valeant Pharmaceuticals, and best known for its contact lenses and branded generic drugs, has declined by more than 35% this year, due to the impact of Covid-19 on its business.A Covid recession will impact the company’s revenues and cash flows.

Does Bausch Health Have Enough Cash For A Covid-19 Led Recession?

The Buy Case For Bausch Health

Comparing the trend in Bausch Health Companies’ stock, best known for its contact lenses and branded generic drugs, over recent months with its trajectory during and after the Great Recession of 2008, we believe that the stock can potentially gain 15% once fears surrounding the coronavirus.

What’s Next For Bausch Health Stock After 50% Rally?

Bausch Health Companies Inc. (BHC) CEO Joe Papa Presents at Goldman Sachs Global Healthcare Conference Call (Transcript)

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Bausch (BHC) Up 21.2% Since Last Earnings Report: Can It Continue?

Bausch Health Companies, best known for its contact lenses and branded generic drugs, has seen its stock fall more than 35% year-to-date, as the coronavirus pandemic is expected to have a meaningful impact on its businesses. BHC stock also remains down by about 11% from levels seen in early 2018.

After 35% Decline Does Bausch Health Companies Stock Look Attractive?

Tivity Health

Investing in companies that are forced to write down their assets due to botched acquisitions can have devastating consequences for investors.

2 Healthcare Stocks At High Risk Of A Writedown

TransDigm

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Notable Insider Buys: Bausch, TransDigm And More

Bausch Health's Turnaround Is Underway

Bausch Health Cos. Inc. BHC, +5.92% , the company formerly known as Valeant, said Monday it has launched an offering of $1.25 billion of new senior notes that mature in 2029.

Bausch Health launches offering of $1.25 billion in senior notes that mature in 2029

Bausch (BHC) misses on earnings and sales in the first quarter and lowers guidance due to the coronavirus pandemic.

Bausch (BHC) Down on Q1 Earnings & Sales Miss, View Trimmed

Bausch Health Companies Inc (BHC) CEO Joe Papa on Q1 2020 Results - Earnings Call Transcript

Shares of Bausch Health Companies Inc. BHC, +2.02% sank 3.6% in premarket trading Thursday, after the drug and medical-device products maker reported a wider net loss and a surprise decline in revenue given the negative effects of the COVID-19 pandemic.

Bausch Health's stock drops after a surprise decline in revenue and lowered outlook

Bausch (BHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bausch Health (BHC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

How one company's enormous debt stack is preventing a fresh start.

Does $24.6 Billion in Debt Make Bausch Health Companies Too Risky a Buy?

Bausch (BHC) begins a clinical study on Virazole in combination with standard-of-care therapy to treat adults with respiratory distress due to COVID-19 in Canada.

Bausch (BHC) Starts Study on Virazole for Coronavirus Infection

Align Technology

Shockwave Medical

Optimism that the worst might be over with the COVID-19 outbreak fueled investors' enthusiasm for these healthcare stocks.

Why Align Technology, Bausch Health, Momenta Pharmaceuticals, and ShockWave Medical Stocks Soared Today

Despite its high debt levels, Bausch Health is well positioned to survive an economic downturn because of its healthy cash flow.

Bausch Health Companies: The Sell-Off Looks Overdone

Bausch Health Companies (NYSE: BHC) shares were trading higher on Tuesday, after the company announced a study arm evaluating 40 mg BID of Rifaximin SSD IR in combination with standard of care therapy met primary endpoint.

Why Bausch Health's Stock Is Trading Higher Today

Bausch Health Companies: Debt, Cash And Goodwill

Unique Opportunity To Double Dip With Bausch Health

Why Is Bausch (BHC) Down 46.5% Since Last Earnings Report?

Exact Sciences

More coronavirus worries. More misery for these healthcare stocks.

Why Align Technology, Bausch Health, and Exact Sciences Stocks Tanked Today

The stock rebounded on Friday in lockstep with the broader biopharmaceutical industry.

News for Bausch Health Companies Inc Stock (BHC)